Neuroscientific Biopharmaceuticals (NSB) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASX
NeuroScientific locks in key US FDA meeting
NeuroScientific has locked in a key meeting with the US FDA for its StemSmart technology aimed at treating refractory Crohn’s disease in a planned Phase 2 trial.
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Google NewsIs NeuroScientific Biopharmaceuticals (ASX: NSB) Still Worth Watching After Today's Drop? - Kalkine
Is NeuroScientific Biopharmaceuticals (ASX: NSB) Still Worth Watching After Today's Drop? Kalkine
Change of Director's Interest Notice x2
director_dealing announcement
Daily Special: ClearVue Technologies, NeuroScientific Biopharmaceuticals, Lithium Energy - Sharecafe
Daily Special: ClearVue Technologies, NeuroScientific Biopharmaceuticals, Lithium Energy Sharecafe
Small Caps
NeuroScientific hails 80% clinical response in Crohn’s stem cell program
NeuroScientific Biopharmaceuticals has reported an 80% response rate from five Crohn’s disease patients treated with its StemSmart cell therapy, with all patients showing improvement.
Why NeuroScientific Biopharmaceuticals (ASX:NSB) Shares are Trading Higher on Tuesday? - Kalkine
Why NeuroScientific Biopharmaceuticals (ASX:NSB) Shares are Trading Higher on Tuesday? Kalkine
NeuroScientific (ASX:NSB) hits 80% Crohn's response and pulls forward Australian approval - Stocks Down Under
NeuroScientific (ASX:NSB) hits 80% Crohn's response and pulls forward Australian approval Stocks Down Under
Remarkable Results from Patients treated with StemSmart
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
StemSmart Manufacturing Scale-Up Transfer Advances
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Successful Clinical Results Achieved under Special Access
other announcement
Fourth Patient Commences StemSmart MSC Treatment
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
First Patients Approved for Special Access Program
other announcement
Date of AGM & Closing Date for Director Nominations
other announcement
Notification regarding unquoted securities - NSB
other announcement
Previous StemSmart Studies Support Renal Transplantation
other announcement
Presentation - TechKnow Invest Roadshow Conference
other announcement
NeuroScientific Partners with Leading Biologic Manufacturer
other announcement
Experienced Cell Therapy Executive Appointed CEO
other announcement
Dr Catherine Cole Appointed as Chief Medical Officer
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Change of Director's Interest Notice (AU)
director_dealing announcement
Breakthrough Stem Cell Tech Acquired-StemSmart Presentation
other announcement
Change of Director's Interest Notice x2
director_dealing announcement